Cargando…

Corrigendum to “Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori”

Detalles Bibliográficos
Autores principales:	Zhang, Lingyun, Lan, Yu, Wang, Qi, Zhang, Yuexia, Si, Xiaobei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169254/ https://www.ncbi.nlm.nih.gov/pubmed/34122540 http://dx.doi.org/10.1155/2021/9823426

Ejemplares similares

Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori
por: Zhang, Lingyun, et al.
Publicado: (2019)

Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori
por: Wang, Junxian, et al.
Publicado: (2021)

Levofloxacin-containing triple therapy versus bismuth-based quadruple therapy as regimens for second line anti- Helicobacter pylori
por: Seyyedmajidi, Mohamadreza, et al.
Publicado: (2019)

Effects of 14-days bismuth- and tetracycline-containing quadruple therapy with concomitant regimen for the first line Helicobacter pylori eradication
por: Kazemi Veysari, Arash, et al.
Publicado: (2023)

Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes
por: Kim, Sung Eun, et al.
Publicado: (2017)

Effect of gastric microbiota on quadruple Helicobacter pylori eradication therapy containing bismuth
por: Niu, Zhan-Yue, et al.
Publicado: (2021)

The Comparison of Levofloxacin- and Clarithromycin-Based Bismuth Quadruple Therapy Regimens in Helicobacter pylori Eradication
por: Arj, Abbas, et al.
Publicado: (2020)

Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection
por: Jheng, Guang-Hong, et al.
Publicado: (2015)

Efficacy of a bismuth-based quadruple therapy regimen for Helicobacter pylori eradication in Saudi Arabia
por: Alsohaibani, Fahad, et al.
Publicado: (2020)

Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial
por: Suo, Baojun, et al.
Publicado: (2023)

Inefficacy of Triple Therapy and Comparison of Two Different Bismuth-containing Quadruple Regimens as a Firstline Treatment Option for Helicobacter pylori
por: Kekilli, Murat, et al.
Publicado: (2016)

Comparison of quadruple and triple Furazolidone containing regimens on eradication of helicobacter pylori
por: Mokhtare, Marjan, et al.
Publicado: (2015)

Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori
por: Gisbert, Javier P, et al.
Publicado: (2012)

Susceptibility-guided bismuth quadruple therapies for resistant Helicobacter pylori infections
por: Yang, Tiankuo, et al.
Publicado: (2020)

A Comparison Between Dexlansoprazole Modified Release–Based And Lansoprazole-Based Nonbismuth Quadruple (Concomitant) Therapy For First-Line Helicobacter pylori Eradication: A Prospective Randomized Trial [Corrigendum]
Publicado: (2019)

Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication
por: Huh, Ki Young, et al.
Publicado: (2021)

Multiple Bismuth Quadruple Therapy Containing Tetracyclines Combined with Other Antibiotics and Helicobacter pylori Eradication Therapy
por: Sun, Yingchao, et al.
Publicado: (2022)

Optimal treatment duration of bismuth-containing quadruple therapy in Helicobacter pylori infection: A retrospective study
por: Kim, Ji Yoon, et al.
Publicado: (2023)

Second-Line Bismuth-Containing Quadruple Therapy for Helicobacter pylori Infection: A 12-Year Study of Annual Eradication Rates
por: Shin, Kiwon, et al.
Publicado: (2021)

Efficacy of Twice a Day Bismuth Quadruple Therapy for Second-Line Treatment of Helicobacter pylori Infection
por: Kim, Jeemyoung, et al.
Publicado: (2022)

Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: A comparative, open trial
por: Choi, Youn I, et al.
Publicado: (2019)

Efficacy of Clarithromycin Containing Bismuth–Based Regimen as a Second-Line Therapy in Helicobacter Pylori Eradication
por: Mokhtare, Marjan, et al.
Publicado: (2015)

Seven Days of Bismuth-Based Quadruple Therapy Is as Effective for the First-Line Treatment of Clarithromycin-Resistant Confirmed Helicobacter pylori Infection as 14 Days of Bismuth-Based Quadruple Therapy
por: Moon, Sang-Gon, et al.
Publicado: (2022)

Susceptibility-Guided Therapy vs. Bismuth-Containing Quadruple Therapy as the First-Line Treatment for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis
por: Ouyang, Yaobin, et al.
Publicado: (2022)

Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication
por: Yoon, Jai Hoon, et al.
Publicado: (2012)

Modified quadruple therapy versus bismuth-containing quadruple therapy in first-line treatment of Helicobacter pylori infection in Korea; rationale and design of an open-label, multicenter, randomized controlled trial
por: Lim, Hyun, et al.
Publicado: (2018)

Rescue effects of Lactobacillus-containing bismuth regimens after Helicobacter pylori treatment failure
por: Karbalaei, M., et al.
Publicado: (2021)

Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication
por: Huang, Hsiang Tso, et al.
Publicado: (2018)

Empiric “Three-in-One” Bismuth Quadruple Therapy for Second-Line Helicobacter pylori Eradication: An Intervention Study in Southern Italy
por: Losurdo, Giuseppe, et al.
Publicado: (2022)

Comparison between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Trial
por: Fathy El Sayed, Ayman, et al.
Publicado: (2021)

The efficacy and safety of furazolidone-bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotic supplementation
por: Noorbakhsh, Nafeh, et al.
Publicado: (2022)

Bismuth-Based Quadruple Therapy for Clarithromycin-Resistant Helicobacter pylori Infection: Effectiveness and Cost-Efficiency
por: Lee, Moon Won, et al.
Publicado: (2022)

Identifying the best regimen for primary eradication of Helicobacter pylori: analysis of 240 cases
Publicado: (2021)

Eradication efficacy of high-dose amoxicillin and proton pump inhibitor compared with quadruple therapy contained bismuth in the treatment of Helicobacter pylori
por: Hajiani, Eskandar, et al.
Publicado: (2022)

Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial
por: Su, Jing, et al.
Publicado: (2017)

Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori
por: Niu, Min, et al.
Publicado: (2022)

The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance
por: Huang, Tzu-Hsin, et al.
Publicado: (2021)

Effects of Clarithromycin-Containing Quadruple Therapy on Helicobacter Pylori Eradication after Nitroimidazole-Containing Quadruple Therapy Failure
por: Fakheri, Hafez, et al.
Publicado: (2016)

Efficacy of a quadruple therapy regimen for Helicobacter pylori eradication after partial gastrectomy
por: Zhang, F., et al.
Publicado: (2016)

Clarithromycin versus Gemifloxacin in Quadruple Therapeutic Regimens for Helicobacter Pylori Infection Eradication
por: Mansour-Ghanaei, Fariborz, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_an2bsjravoeshs4ctimvo6ume7